04th November 2026

To
The Corporate Relations Department
BSE Limited
Phiroz Jeejeebhoy Towers, 25th Floor,
Dalal Street,
Mumbai- 400001
Scrip Code - 543308
ISIN: INE967H01025

To
The Listing Department
National Stock Exchange of India Limited
Exchange Plaza,
Bandra Kurla Complex, Bandra (East),
Mumbai - 400 051
Symbol - KIMS
ISIN: INE967H01025

Dear Sir/Madam,

Sub: Outcome of Board Meeting held on 04th November 2026 pursuant to Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Further to our intimation of the Board Meeting dated 26th October 2026, the Board of Directors, at its meeting held today, has approved the following:

a) Unaudited (Standalone and Consolidated) financial results of the Company for the 02nd quarter and half-year ended 30th September 2026 together with the Limited Review Reports issued by the statutory auditors of the Company and as reviewed by the Audit Committee;

b) Approval of merger of wholly-owned subsidiary KIMS Hospitals Private Limited (Transferor Company) with its Holding Company i.e. Krishna Institute of Medical Sciences Limited (Transferee Company);

c) Approval for entering into transaction documents by and between KIMS Swastha Private Limited, Wholly-Owned Subsidiary and LOVR Institute of Medical Sciences Limited for providing Operations and Management (O&M) Agreement for Westfort Hospital, Thrissur;

d) Based on the recommendation of the Nomination and Remuneration Committee, the Board of directors of the company approved the re-appointment of Dr. Abhinay Bollineni (DIN No. 01681273) as Director & CEO of the Company for a further term of 5 years;

e) Based on the recommendation of the Nomination and Remuneration Committee, the Board of directors of the company approved the reappointment of Dr. Bhaskara Rao Bollineni (DIN No. 00008985) as Chairman & Managing Director of the Company for a further term of five years, including continuation in office beyond the age of 70 years;

f) Based on the recommendation of the Nomination and Remuneration Committee, the Board of directors of the company approved the reappointment of Ms. Dandamudi Anitha (DIN No. 00025480) as Whole-time Director of the Company for a term of 5 years.

g) Approval for the postal ballot notice for Reappointment of Dr Abhinay Bollineni as Director and CEO, Dr. Bhaskara Rao Bollineni as Chairman & Managing Director and Ms. Dandamudi Anitha as Whole Director of the Company.

Further, the financial results are also available on the website of the Company at https://www.kimshospitals.com/investors/Disclosures under Regulation 46 of SEBI (LODR) Regulations, 2015/ Financial Information/ Financial Result and on the websites of BSE Ltd and National Stock Exchange of India Ltd viz. www.bseindia.com and www.nseindia.com, respectively.

Further, the financial results will also be published in the newspaper as per the requirement and in the format prescribed under SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.

Board Meeting Commenced at : 02:00 P.M
Board Meeting Concluded at : 06:00 P.M

Thanking you,

For Krishna Institute of Medical Sciences Limited

NAGAJAYANTHI JUTTUR RAGHAVENDRA DAS
Digitally signed by NAGAJAYANTHI JUTTUR RAGHAVENDRA DAS
Date: 2026.11.04 18:37:23 +05'30'

Nagajayanthi J.R
Company Secretary & Compliance Officer

S.R. BATLIBOI & ASSOCIATES LLP
Chartered Accountants

THE SKYVIEW 20
2nd Floor, Unit No: 201 & 202
Left Wing, Survey No. 83/1
Hyderabad - 500 032 India

Tel: +91 40 6141 6000

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Consolidated Financial Results of Krishna Institute of Medical Sciences Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to
The Board of Directors
Krishna Institute of Medical Sciences Limited

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of Krishna Institute of Medical Sciences Limited (the "Holding Company"), its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group") and its associate for the quarter ended September 30, 2026 and year to date from April 01, 2026 to September 30, 2026 (the "Statement") attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

2. The Holding Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Holding Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

   We also performed procedures in accordance with the Master Circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the following entities:

S.No.	Entity	Relationship
1	Krishna Institute of Medical Sciences Limited	Holding Company
2	Arunodaya Hospitals Private Limited	Subsidiary
3	KIMS Hospital Enterprises Private Limited	Subsidiary
4	Iconkrishi Institute of Medical Sciences Private Limited	Subsidiary
5	Saveera Institute of Medical Sciences Private Limited	Subsidiary
6	KIMS Hospital Kurnool Private Limited	Subsidiary
7	KIMS Hospitals Private Limited	Subsidiary
8	KIMS Swastha Private Limited	Subsidiary
9	KIMS Hospital Bengaluru Private Limited	Subsidiary
10	Sarvejana Healthcare Private Limited	Subsidiary
11	SPANV Medisearch Lifesciences Private Limited	Subsidiary
12	KIMS Manavata Hospitals Private Limited	Subsidiary
13	Meda Institute of Podiatry Private Limited	Subsidiary
14	Chalasani Hospitals Private Limited	Subsidiary
15	Kondapur Healthcare Limited	Associate

S.R. BATLIBOI & ASSOCIATES LLP * CHARTERED ACCOUNTANTS * HYDERABAD

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. The accompanying Statement includes the unaudited interim financial results and other financial information, in respect of:

   - Three subsidiaries, whose unaudited interim financial results include total assets of Rs. 5,085 million as at September 30, 2026, total revenues of Rs. 497 million and Rs. 901 million, total net loss after tax of Rs. 39 million and Rs. 84 million, total comprehensive loss of Rs. 39 million and Rs. 85 million, for the quarter ended September 30, 2026 and the period ended on that date respectively, and net cash inflows of Rs. 32 million for the period from April 01, 2026 to September 30, 2026, as considered in the Statement which have been reviewed by their respective independent auditors.

   - An associate, whose unaudited interim financial results include Group's share of net (loss)/profit of Rs. (4) million and Rs. 6 million and Group's share of total comprehensive (loss)/income of Rs. (4) million and Rs. 6 million for the quarter ended September 30, 2026 and for the period from April 01, 2026 to September 30, 2026 respectively, as considered in the Statement whose interim financial results, other financial information have been reviewed by their respective independent auditors.

   The independent auditor's reports on interim financial results of these entities have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures in respect of these subsidiaries and associate is based solely on the report of such auditors and procedures performed by us as stated in paragraph 3 above.

   Our conclusion on the Statement in respect of matters stated in para 6 is not modified with respect to our reliance on the work done and the reports of the other auditors.

For S.R. Batliboi & Associates LLP
Chartered Accountants
ICAI Firm registration number: 101049W/E300004

Mitesh Parikh

S.R. BATLIBOI & ASSOCIATES LLP CHARTERED ACCOUNTANTS HYDERABAD

per Mitesh K Parikh
Partner
Membership No.: 225333
UDIN: 26225333BUEHNN3475
Place: Hyderabad
Date: November 04, 2026

Krishna Institute of Medical Sciences Limited
Corporate Identity number : L55101TG1973PLC040558
Registered office : 1-8-31/1, Ministers road, Secunderabad, 500003, Telangana, India
Website: www.kimshospitals.com, Email: CS@kimshospitals.com, Tel: 040 7122 5000

Statement of Unaudited Consolidated Financial Results for the quarter and half year ended 30 September 2026

(Rupees in millions)

		Quarter Ended			Half year ended		Year ended
		30-Sep-26	30-Jun-26	30-Sep-25	30-Sep-26	30-Sep-25	31-Mar-26
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	**Income**						
	(a) Revenue from operations	13,444	11,795	9,607	25,239	18,323	39,046
	(b) Other income	186	164	42	350	113	262
	Total Income	**13,630**	**11,959**	**9,649**	**25,589**	**18,436**	**39,308**
2	**Expenses**						
	(a) Purchase of medical consumables, drugs and surgical instruments	2,838	2,609	2,035	5,447	3,952	8,418
	(b) Increase in inventories of medical consumables, drugs and surgical instruments	(62)	(162)	(83)	(224)	(160)	(329)
	(c) Employee benefits expense	2,319	2,126	1,745	4,445	3,255	6,817
	(d) Other expenses	5,746	4,988	3,870	10,734	7,310	16,120
	(e) Finance costs	655	834	450	1,489	776	2,025
	(f) Depreciation and amortisation expenses	1,207	1,008	661	2,215	1,195	2,832
	Total Expenses	**12,703**	**11,403**	**8,678**	**24,106**	**16,328**	**35,883**
3	**Profit before share of profit from associate (1-2)**	**927**	**556**	**971**	**1,483**	**2,108**	**3,425**
4	**Share of profit from associate, net of tax**	**(4)**	**10**	**-**	**6**	**-**	**26**
5	**Profit before tax and exceptional items (3+4)**	**923**	**566**	**971**	**1,489**	**2,108**	**3,451**
6	**Exceptional items**	**132**	**-**	**(3)**	**132**	**(3)**	**(112)**
7	**Profit before tax (5+6)**	**1,055**	**566**	**968**	**1,621**	**2,105**	**3,339**
8	**Tax expense**						
	(a) Current tax	360	338	377	698	701	1,362
	(b) Deferred tax credit	(51)	(146)	(129)	(197)	(166)	(443)
	Total tax expense (8)	**309**	**192**	**248**	**501**	**535**	**919**
9	**Profit for the period/year (7-8)**	**746**	**374**	**720**	**1,120**	**1,570**	**2,420**
	Attributable to:						
	Owners of the company	750	415	669	1,165	1,455	2,414
	Non controlling interests	(4)	(41)	51	(45)	115	6
10	**Other comprehensive (loss)/income for the period/year**						
	Items that will not be reclassified subsequently to statement of profit and loss						
	- Re-measurement (loss)/gain on defined benefit plans	(9)	0	4	(9)	(2)	2
	- Income tax effect	2	0	(1)	2	-	-
	Other comprehensive (loss)/income, net of tax	**(7)**	**0**	**3**	**(7)**	**(2)**	**2**
	Attributable to:						
	Owners of the company	(7)	0	2	(7)	(2)	1
	Non controlling interests	-	0	1	-	-	1
11	**Total comprehensive income (9+10)**						
	Owners of the company	743	415	671	1,158	1,453	2,415
	Non controlling interests	(4)	(41)	52	(45)	115	7
	Total comprehensive income for the period/year	**739**	**374**	**723**	**1,113**	**1,568**	**2,422**
12	**Paid up equity share capital (face value of Rs.2 each)**						800
13	**Other Equity**						21,674
14	**Earnings per share (of Rs.2 each): (not annualised for the quarter/period ended)**						
	(a) Basic (Rs.)	1.79	1.04	1.67	2.83	3.64	6.03
	(b) Diluted (Rs.)	1.79	1.04	1.67	2.83	3.64	6.03

Notes:

1 The unaudited consolidated financial results of Krishna Institute of Medical Sciences Limited (the "Holding Company" or the "Company"), its subsidiaries (the Holding Company and its subsidiaries together referred to as the "Group") and its associate have been prepared in accordance with the Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 ("the Act"), as amended, read with relevant rules thereunder, other accounting principles generally accepted in India and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

2 The above results for the quarter and half year ended 30 September 2026 of the Group have been reviewed by the Audit committee and approved by the Board of Directors at their meetings held on 04 November 2026 and have been subject to a limited review by the statutory auditors of the Company. The statutory auditors have expressed an unmodified review opinion on these results.

3 During the previous quarter, the Company had issued 19,867,549 equity shares of face value of Rs 2 each through Qualified Institutions Placement (QIP) at an issue price of Rs. 755 per share (including securities premium of Rs. 753 per share), aggregating Rs. 15,000 million. As at 30 September 2026, funds received pursuant to QIP (net of issue expenses of Rs. 244 million) have been utilised towards the objects stated in the Placement Document and the balance amounts unutilised have been temporarily invested in mutual fund and kept in monitoring account.

4 During the current quarter, pursuant to the shareholders approval and requisite statutory and regulatory approvals, the Company allotted 7,702,182 convertible warrants on 19 August 2026, on a preferential basis to the promoters and promoter group entities, at an issue price of Rs.779 per warrant, aggregating to Rs.6,000 million. Each warrant is convertible into one fully paid-up equity share of face value Rs. 2 each. The Company received Rs. 1,500 million, representing 25% of the issue price, as upfront consideration and the balance 75% is receivable upon exercise of the warrants. The warrants are exercisable, in one or more tranches, within a period of 18 months from the date of allotment, in accordance with the terms of the issue.

5 Subsequent to the current quarter, the Company acquired 51% of the equity share capital of Sarvottam Health Care Private Limited (Trust Multi Speciality Hospital) for a total cash consideration of Rs. 795 million.

6 During the half year ended 30 September 2026, the Group has entered into a Hospital Operations and Management Agreement with an entity engaged in medical services, thereby obtaining control over hospital operations and providing healthcare services using their assets. The transaction has been accounted for as a business combination under Ind AS 103-Business Combinations ("Ind AS 103") based on final purchase price allocation report, with acquisition-related costs of Rs. 3 million included in other expenses.

7 Exceptional items include:
i) Gain / (loss) of Rs. 132 million for the quarter and half year ended 30 September 2026 [(Rs. 3) million for the quarter and half year ended 30 September 2025 and Rs. 102 million for the year ended 31 March 2026] pertains to valuation of call option under the call option agreements executed by the Company to acquire equity stake in entities with whom the Company has Operations and Management agreements to operate and manage their hospitals.
ii) Balance exceptional items for the year ended 31 March 2026 pertains to past service cost arising from changes in definition of wages pursuant to the implementation of the New labour codes.

8 The Unaudited Consolidated Balance sheet and Unaudited Consolidated Statement of Cash Flows are set out in Annexure I and Annexure II respectively.

9 The Group operates in one single reportable business segment - "Medical and Healthcare services".

10 The above Unaudited Consolidated Financial Results of the Group are available on the Company's website www.kimshospitals.com and also on the website of BSE (www.bseindia.com) and NSE (www.nseindia.com), where the shares of the Company are listed.

For and on behalf of the Board
Krishna Institute of Medical Sciences Limited

Dr. B Bhaskara Rao
Managing Director
DIN: 00008303

Hyderabad
04 November 2026

IDENTIFICATION PURPOSES ONLY S.R. BATLIBOI & ASSOCIATES LLP CHARTERED ACCOUNTANTS HYDERABAD

Annexure - I

Krishna Institute of Medical Sciences Limited

Corporate Identity number : L55101TG1973PLC040558

Registered office : 1-8-31/1, Ministers road, Secunderabad, 500003, Telangana, India

Website: www.kimshospitals.com, Email: CS@kimshospitals.com, Tel: 040 7122 5000

Unaudited Consolidated Balance Sheet as at 30 September 2026

(Rupees in millions)

	Particulars	As at 30 September 2026 (Unaudited)	As at 31 March 2026 (Audited)
A	**ASSETS**		
1	**Non-current Assets**		
	Property, plant and equipment	47,977	41,862
	Capital work-in-progress	5,178	6,062
	Goodwill	3,386	3,386
	Other Intangible assets	524	570
	Right-of-use assets	11,355	11,283
	Investments accounted for using equity method	898	875
	Financial assets		
	(i) Investments	6	6
	(ii) Loans	876	134
	(iii) Other financial assets	710	778
	Deferred tax asset (net)	1,563	1,274
	Non-current tax assets (net)	872	550
	Other non-current assets	1,006	1,433
	Total Non-current Assets - (1)	**74,351**	**68,213**
2	**Current Assets**		
	Inventories	1,193	969
	Financial assets		
	(i) Investments	3,224	151
	(ii) Trade receivables	6,906	5,542
	(iii) Cash and cash equivalents	528	554
	(iv) Bank balances other than (iii) above	286	193
	(v) Loans	780	722
	(vi) Other financial assets	1,050	675
	Other current assets	802	568
	Total Current Assets - (2)	**14,769**	**9,374**
3	**Total Assets (3) = (1)+(2)**	**89,120**	**77,587**
B	**EQUITY AND LIABILITIES**		
4	**Equity**		
	Equity share capital	840	800
	Other equity	38,478	21,674
	Equity attributable to Shareholders of the company - (4)	**39,318**	**22,474**
5	Non-controlling interests - (5)	3,204	3,111
6	**Total Equity (6) = (4)+(5)**	**42,522**	**25,585**
7	**Non-current liabilities**		
	Financial liabilities		
	(i) Borrowings	19,351	26,726
	(ii) Lease liabilities	9,789	9,648
	(iii) Other financial liabilities	1,590	1,494
	Provisions	498	457
	Other non-current liabilities	483	608
	Deferred tax liabilities (net)	761	680
	Total Non-current liabilities - (7)	**32,472**	**39,613**
8	**Current liabilities**		
	Financial liabilities		
	(i) Borrowings	5,948	5,714
	(ii) Lease liabilities	295	441
	(iii) Trade payables		
	(a) Total outstanding dues of micro enterprises and small enterprises; and	1,071	534
	(b) Total outstanding dues of creditors other than micro enterprises and small enterprises	3,684	2,694
	(iv) Other financial liabilities	1,726	1,900
	Provisions	332	326
	Other current liabilities	1,019	780
	Current tax liabilities (net)	51	-
	Total Current liabilities - (8)	**14,126**	**12,389**
9	**Total Equity and Liabilities (9) = (6)+(7)+(8)**	**89,120**	**77,587**

FOR IDENTIFICATION PURPOSES ONLY
S.R. BATLIBOI & ASSOCIATES LLP
CHARTERED ACCOUNTANTS
HYDERABAD

Krishna Institute of Medical Sciences Ltd
Sec'bad

Annexure - II

Krishna Institute of Medical Sciences Limited
Corporate Identity number : L55101TG1973PLC040558
Registered office : 1-8-31/1, Ministers road, Secunderabad, 500003, Telangana, India
Website: www.kimshospitals.com, Email: CS@kimshospitals.com, Tel: 040 7122 5000

Statement of Unaudited Consolidated Cash flows for the half year ended 30 September 2026

(Rupees in millions)

Particulars	For the half year ended	
	30-Sep-26 (Unaudited)	30-Sep-25 (Unaudited)
I. Cash flows from operating activities:		
Profit before tax for the period	1,621	2,105
Adjustments for operating activities:		
Depreciation and amortisation expenses	2,215	1,195
Finance costs	1,489	776
Loss on sale of property, plant and equipment (net)	17	3
Provision of expected credit loss for trade receivables (including bad debts)	71	34
Interest income	(115)	(47)
Deferred Government grants income	(107)	(16)
Liabilities no longer required written back	(4)	(3)
Gain on mutual funds	(58)	(4)
Rental income	(13)	(7)
Fair value loss on liability on business combanation	6	-
(Gain)/loss on fair valuation of Call option (net)	(132)	3
Gain on termination of lease	(5)	-
Share of profit from associate	(6)	-
Operating cash flows before working capital changes	**4,979**	**4,039**
Adjustments for:		
Increase		
- in Trade receivables	(1,435)	(924)
- in Inventories	(224)	(160)
- in Other financial assets and other assets	(516)	(246)
Increase in trade payables, other financial liabilities, provisions and other liabilities	1,627	894
Cash generated from operations	**4,431**	**3,603**
Income taxes paid, net of refunds	(981)	(757)
Net cash generated from operating activities (1)	**3,450**	**2,846**
II. Cash flows from investing activities		
Purchase of property, plant and equipment and other intangible assets, including capital work-in-progress and capital advances	(6,541)	(7,533)
Proceeds from sale of property, plant and equipment	16	136
Investment in associate	(17)	(10)
Investment in mutual funds	(10,501)	(840)
Proceeds from sale of mutual funds	7,486	863
Loans given	(1,247)	(207)
Loans repayment received	483	364
Redemption of bank deposits (having original maturity of more than three months)	52	116
Investment in bank deposits (having original maturity of more than three months)	(71)	(80)
Rental income received	13	7
Interest received	58	19
Net cash used in investing activities (2)	**(10,269)**	**(7,165)**
III. Cash flows from financing activities		
Proceeds from long-term borrowings	3,625	5,232
Repayment of long-term borrowings	(10,710)	(1,197)
(Repayment)/proceeds from short-term borrowings (net)	(74)	2,014
Issue of preference shares to non-controlling interest	-	243
Acquisition of non-controlling interest	(338)	(239)
Acquisition of business	(337)	-
Proceeds from issue of shares (net of issue expenses)	14,756	-
Proceeds from issue of share warrants	1,500	-
Share application money (refunded to)/received from non-controlling interest	(8)	115
Advance paid for acquisition of non-controlling interest	-	(360)
Payment of principal of lease liability	(174)	(25)
Payment of interest on lease liability	(276)	(265)
Interest paid	(1,171)	(952)
Net cash flows generated from financing activities (3)	**6,793**	**4,566**
Net (decrease)/increase in cash and cash equivalents (1+2+3)	(26)	247
Cash and cash equivalents at the beginning of the period	554	560
Cash and cash equivalents at the end of the period	**528**	**807**
Components of cash and cash equivalents		
Cash on hand	35	46
Balances with banks		
- On current accounts	347	761
- In deposit accounts (with original maturity of 3 months or less)	146	-
Total	**528**	**807**

FOR IDENTIFICATION PURPOSES ONLY
S.R. BATLIBOI & ASSOCIATES LLP
CHARTERED ACCOUNTANTS
HYDERABAD

S.R. BATLIBOI & ASSOCIATES LLP
Chartered Accountants

THE SKYVIEW 20
2nd Floor, Unit No: 201 & 202
Left Wing, Survey No. 83/1
Hyderabad - 500 032 India

Tel: +91 40 6141 6000

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of Krishna Institute of Medical Sciences Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to
The Board of Directors
Krishna Institute of Medical Sciences Limited

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of Krishna Institute of Medical Sciences Limited (the "Company") for the quarter ended September 30, 2026 and year to date from April 01, 2026 to September 30, 2026 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").


2. The Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For S.R. BATLIBOI & ASSOCIATES LLP
Chartered Accountants
ICAI Firm registration number: 101049W/E300004





per Mitesh K Parikh
Partner
Membership No.: 225333
UDIN: 26225333ULKENN7635
Place: Hyderabad
Date: November 04, 2026

Krishna Institute of Medical Sciences Limited
Corporate Identity number : L55101TG1973PLC040558
Registered office : 1-8-31/1, Ministers road, Secunderabad, 500003, Telangana, India
Website: www.kimshospitals.com, Email: CS@kimshospitals.com, Tel: 040 7122 5000

Statement of Unaudited Standalone Financial Results for the quarter and half year ended 30 September 2026

(Rupees in millions)

		Quarter ended			Half year ended		Year ended
		30-Sep-26 (Unaudited)	30-Jun-26 (Unaudited)	30-Sep-25 (Unaudited)	30-Sep-26 (Unaudited)	30-Sep-25 (Unaudited)	31-Mar-26 (Audited)
1	**Income**						
	(a) Revenue from operations	5,243	4,836	4,300	10,079	8,034	17,015
	(b) Other income	278	307	125	585	247	566
	Total Income	**5,521**	**5,143**	**4,425**	**10,664**	**8,281**	**17,581**
2	**Expenses**						
	(a) Purchase of medical consumables, drugs and surgical instruments	1,022	999	917	2,021	1,698	3,468
	(b) Decrease/(increase) in inventories of medical consumables, drugs and surgical instruments	13	(39)	(63)	(26)	(86)	(135)
	(c) Employee benefits expense	919	849	761	1,768	1,443	2,907
	(d) Other expenses	2,048	1,845	1,563	3,893	2,882	6,096
	(e) Finance costs	118	328	178	446	303	787
	(f) Depreciation and amortisation expenses	300	273	205	573	380	861
	Total Expenses	**4,420**	**4,255**	**3,561**	**8,675**	**6,620**	**13,984**
3	**Profit before tax and exceptional items (1-2)**	**1,101**	**888**	**864**	**1,989**	**1,661**	**3,597**
4	**Exceptional items**	**132**	**-**	**(3)**	**132**	**(3)**	**(70)**
5	**Profit before tax (3+4)**	**1,233**	**888**	**861**	**2,121**	**1,658**	**3,527**
6	**Tax expense**						
	(a) Current tax	279	200	187	479	361	745
	(b) Deferred tax charge	25	23	39	48	74	175
	Total tax expense (6)	**304**	**223**	**226**	**527**	**435**	**920**
7	**Profit for the period/year (5-6)**	**929**	**665**	**635**	**1,594**	**1,223**	**2,607**
8	**Other comprehensive (loss)/income for the period/year**						
	Items that will not be reclassified subsequently to statement of profit and loss						
	- Re-measurement (loss)/gain on defined benefit plans	(5)	(0)	2	(5)	(2)	0
	- Income tax effect	1	0	-	1	1	(0)
	Other comprehensive (loss)/income, net of tax	**(4)**	**(0)**	**2**	**(4)**	**(1)**	**0**
9	**Total comprehensive income for the period/year (7+8)**	**925**	**665**	**637**	**1,590**	**1,222**	**2,607**
10	**Paid up equity share capital (face value of Rs.2 each)**						800
11	**Other Equity**						23,487
12	**Earnings per share (of Rs.2 each) : (not annualised for the quarter/period ended)**						
	(a) Basic (Rs.)	2.21	1.66	1.59	3.87	3.06	6.52
	(b) Diluted (Rs.)	2.21	1.66	1.59	3.87	3.06	6.52

Notes:

1 The unaudited standalone financial results of Krishna Institute of Medical Sciences Limited (the "Company"), have been prepared in accordance with the Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 ("the Act"), as amended, read with relevant rules thereunder, other accounting principles generally accepted in India and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

2 The above results for the quarter and half year ended 30 September 2026 of the Company have been reviewed by the Audit committee and approved by the Board of Directors at their meetings held on 04 November 2026 and have been subject to a limited review by the statutory auditors of the Company. The statutory auditors have expressed an unmodified review opinion on these results.

3 During the previous quarter, the Company had issued 19,867,549 equity shares of face value of Rs 2 each through Qualified Institutions Placement (QIP) at an issue price of Rs. 755 per share (including securities premium of Rs. 753 per share), aggregating Rs. 15,000 million. As at 30 September 2026, funds received pursuant to QIP (net of issue expenses of Rs. 244 million) have been utilised towards the objects stated in the Placement Document and the balance amounts unutilised have been temporarily invested in mutual fund and kept in monitoring account.

4 During the current quarter, pursuant to the shareholders approval and requisite statutory and regulatory approvals, the Company allotted 7,702,182 convertible warrants on 19 August 2026, on a preferential basis to the promoters and promoter group entities, at an issue price of Rs.779 per warrant, aggregating to Rs.6,000 million. Each warrant is convertible into one fully paid-up equity share of face value Rs. 2 each. The Company received Rs. 1,500 million, representing 25% of the issue price, as upfront consideration and the balance 75% is receivable upon exercise of the warrants. The warrants are exercisable, in one or more tranches, within a period of 18 months from the date of allotment, in accordance with the terms of the issue.

5 Subsequent to the current quarter, the Company acquired 51% of the equity share capital of Sarvottam Health Care Private Limited (Trust Multi Speciality Hospital) for a total cash consideration of Rs. 795 Million.

6 Exceptional items include:
i) Gain / (loss) of Rs. 132 million for the quarter and half year ended 30 September 2026 [(Rs. 3) million for the quarter and half year ended 30 September 2025 and Rs. 102 million for the year ended 31 March 2026] pertains to valuation of call option under the call option agreements executed by the Company to acquire equity stake in entities with whom the Company has Operations and Management agreements to operate and manage their hospitals.
ii) Balance exceptional items for the year ended 31 March 2026 pertains to past service cost arising from changes in definition of wages pursuant to the implementation of the New labour codes.

7 The Unaudited Standalone Balance sheet and Unaudited Standalone Statement of Cash Flows are set out in Annexure I and Annexure II respectively.

8 The Company operates in one single reportable business segment - "Medical and Healthcare services".

9 The above Unaudited Standalone Financial Results of the Company are available on the Company's website www.kimshospitals.com and also on the website of BSE (www.bseindia.com) and NSE (www.nseindia.com), where the shares of the Company are listed.

For and on behalf of the Board
Krishna Institute of Medical Sciences Limited

Dr. B Bhaskara Rao
Managing Director
DIN: 00008985

Hyderabad
04 November 2026

FOR IDENTIFICATION PURPOSES ONLY ★ S.R. BATLIBOI & ASSOCIATES LLP ★ HYDERABAD ★ CHARTERED ACCOUNTANTS ★

Krishna Institute of Medical Sciences Ltd ★ Sec'bad ★

Annexure - I

Krishna Institute of Medical Sciences Limited

Corporate Identity number : L55101TG1973PLC040558

Registered office : 1-8-31/1, Ministers road, Secunderabad, 500003, Telangana, India

Website: www.kimshospitals.com, Email: CS@kimshospitals.com, Tel: 040 7122 5000

Unaudited Standalone Balance Sheet as at 30 September 2026

(Rupees in millions)

	Particulars	As at 30 September 2026 (Unaudited)	As at 31 March 2026 (Audited)
A	**ASSETS**		
1	**Non-current Assets**		
	Property, plant and equipment	14,336	13,976
	Capital work-in-progress	1,925	1,160
	Intangible assets	228	220
	Right-of-use assets	1,136	1,140
	Financial assets		
	(i) Investments	19,182	15,228
	(ii) Loans	7,306	6,201
	(iii) Other financial assets	293	199
	Non-current tax assets (net)	16	35
	Other non-current assets	274	354
	Total Non-current Assets - (1)	**44,696**	**38,513**
2	**Current Assets**		
	Inventories	424	398
	Financial assets		
	(i) Investments	3,224	-
	(ii) Trade receivables	3,269	2,784
	(iii) Cash and cash equivalents	183	251
	(iv) Bank balances other than (iii) above	27	49
	(v) Loans	278	261
	(vi) Other financial assets	328	325
	Other current assets	406	270
	Total Current Assets - (2)	**8,139**	**4,338**
3	**Total Assets (3) = (1)+(2)**	**52,835**	**42,851**
B	**EQUITY AND LIABILITIES**		
4	**Equity**		
	Equity share capital	840	800
	Other equity	41,293	23,487
	Total Equity - (4)	**42,133**	**24,287**
5	**Non-current liabilities**		
	Financial liabilities		
	(i) Borrowings	3,658	11,032
	(ii) Lease liabilities	754	724
	(iii) Other financial liabilities	66	98
	Provisions	279	255
	Other non-current liabilities	109	241
	Deferred tax liabilities (net)	603	567
	Total Non-current liabilities - (5)	**5,469**	**12,917**
6	**Current liabilities**		
	Financial liabilities		
	(i) Borrowings	2,670	3,496
	(ii) Lease liabilities	11	11
	(iii) Trade payables		
	(a) Total outstanding dues of micro enterprises and small enterprises; and	335	250
	(b) Total outstanding dues of creditors other than micro enterprises and small enterprises	1,150	886
	(iv) Other financial liabilities	299	344
	Provisions	176	181
	Other current liabilities	541	479
	Current tax liabilities (net)	51	-
	Total Current liabilities - (6)	**5,233**	**5,647**
7	**Total Equity and Liabilities (7) = (4)+(5)+(6)**	**52,835**	**42,851**

FOR IDENTIFICATION PURPOSES ONLY
S.R. BATLIBOI & ASSOCIATES LLP
CHARTERED ACCOUNTANTS
HYDERABAD

Krishna Institute of Medical Sciences Ltd.
Sec'bad

Annexure - II

Krishna Institute of Medical Sciences Limited

Corporate Identity number : L55101TG1973PLC040558

Registered office : 1-8-31/1, Ministers road, Secunderabad, 500003, Telangana, India

Website: www.kimshospitals.com, Email: CS@kimshospitals.com, Tel: 040 7122 5000

Statement of Unaudited Standalone Cashflows for the half year ended 30 September 2026

(Rupees in millions)

Particulars	For the half year ended	
	30-Sep-26	30-Sep-25
	(Unaudited)	(Unaudited)
I. Cash flows from operating activities:		
Profit before tax for the period	2,121	1,658
Adjustments for operating activities:		
Depreciation and amortisation expense	573	380
Loss / (profit) on sale of property, plant and equipment (net)	15	(7)
Provision of expected credit loss for trade receivables (including bad debts)	44	25
Rental income	(1)	-
Interest income	(391)	(214)
Dividend income	(56)	-
Deferred Government grants income	(62)	(16)
(Gain)/loss on fair valuation of Call option (net)	(132)	3
Gain on mutual funds	(57)	(0)
Finance costs	446	303
Operating cash flows before working capital changes	**2,500**	**2,132**
Adjustments for:		
Increase		
- in trade receivables	(529)	(593)
- in inventories	(26)	(86)
- in other financial assets and other assets	(158)	(146)
Increase in trade payables, other financial liabilities, provisions and other liabilities	362	369
Cash generated from operations	**2,149**	**1,676**
Income taxes paid, net of refunds	(420)	(306)
Net cash generated from operating activities (1)	**1,729**	**1,370**
II. Cash flows from investing activities		
Purchase of property, plant and equipment and other intangible assets, including capital work-in-progress and capital advances	(1,693)	(1,868)
Proceeds from sale of property, plant and equipment	16	15
Investment in subsidiaries	(3,945)	(449)
Redemption of preference shares	45	-
Advance for investment in subsidiary	-	(360)
Investment in mutual funds	(10,301)	(470)
Proceeds from sale of mutual funds	7,134	270
Loans given to subsidiaries	(2,099)	(2,212)
Loans repaid by subsidiaries	1,196	593
Redemption of bank deposits (having original maturity of more than three months)	24	13
Investment in bank deposits (having original maturity of more than three months)	(10)	(10)
Dividend received	56	-
Rental income received	1	-
Interest received	173	32
Net cash flows used in investing activities (2)	**(9,403)**	**(4,446)**
III. Cash flows from financing activities		
Proceeds from long-term borrowings	287	1,939
Repayment of long-term borrowings	(7,929)	(279)
(Repayment)/proceeds from short-term borrowings (net)	(572)	1,783
Payment of lease obligations	(12)	-
Proceeds from issue of shares (net of issue expenses)	14,756	-
Proceeds from issue of share warrants	1,500	-
Interest paid	(424)	(333)
Net cash flows generated from financing activities (3)	**7,606**	**3,110**
Net (decrease)/increase in cash and cash equivalents (1+2+3)	(68)	34
Cash and cash equivalents at the beginning of the period	251	261
Cash and cash equivalents at the end of the period	**183**	**295**
Components of cash and cash equivalents		
Cash on hand	15	31
Balances with banks		
- On current accounts	160	264
- In deposit accounts	8	-
Total	**183**	**295**

FOR IDENTIFICATION PURPOSES ONLY
S.R. BATLIBOI & ASSOCIATES LLP
CHARTERED ACCOUNTANTS
HYDERABAD

Krishna Institute of Medical Sciences Ltd.
Sec'bad